Cart
sales@molnova.com
Iroxanadine
CAS No. 203805-20-3
Iroxanadine( —— )
Catalog No. M34287 CAS No. 203805-20-3
Iroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 333 | In Stock |
|
| 10MG | 504 | In Stock |
|
| 25MG | 816 | In Stock |
|
| 50MG | 1097 | In Stock |
|
| 100MG | 1479 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2967 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIroxanadine
-
NoteResearch use only, not for human use.
-
Brief DescriptionIroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.
-
DescriptionIroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.CAS 13480-84-5
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number203805-20-3
-
Formula Weight260.33
-
Molecular FormulaC14H20N4O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(C1NC(=NOC1)C=2C=CC=NC2)N3CCCCC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Darizmetinib
Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
-
TAK-715
A potent, selective, orally active p38α MAPK inhibitor with IC50 of 7.1 nM.
-
Kamebakaurine
Kamebakaurin has the ability to protect the liver from APAP-induced hepatotoxicity, presumably by both inhibiting the inflammatory response and oxidative stress.
